Bone Biologics Corp (BBLG) — Institutional Holders, Q2 2026
4 institutional investment managers reported a BBLG position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $435.8K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BBLG in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
New positions
0
Added to
2
Trimmed
1
Sold out
0
Biggest buyers
- CITADEL ADVISORSAdded · +20,525 sh+$164.2K
- UBS Group AGAdded · +35 sh+$280.00
Biggest sellers
None this quarter.
BBLG 13F holders ranked 1–4 of 4
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS#1 · 50,277 sh | 50,277 | $428.7K | 0.00% | +69.0% |
| 2 | UBS Group AG#2 · 513 sh | 513 | $4.1K | 0.00% | +7.3% |
| 3 | Tower Research Capital (TRC)#3 · 1,953 sh | 1,953 | $2.7K | <0.01% | -52.7% |
| 4 | SBI Securities , Ltd.#4 · 230 sh | 230 | $315.00 | — | 0.0% |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.